CD79b
Part of the B-cell receptor found on nearly all B-cell lymphomas; the target of the ADC polatuzumab vedotin and a frequently mutated gene in brain and testicular lymphoma. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Transmembrane Ig-superfamily protein with an ITAM motif; together with CD79a it couples antigen binding to SYK/BTK/PI3K signalling and mediates BCR internalisation.
- DLBCL (>95% expression; ~20% CD79B mutation in ABC subtype)
- Follicular and mantle cell lymphoma (expression)
- Primary CNS lymphoma (CD79B mutation ~60%)
- CLL (lower expression)
Elsewhere: identifiers and databases
Built from HGNC, Ensembl, UniProt and ChEMBL idsHow common it is, by cancer
Full matrix →| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Diffuse large B-cell lymphoma | 95% | surface expression | doi.org | |
| Primary CNS lymphoma | 50-70% | CD79B mutation |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Products by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes that involve this target
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways where it is a node
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics and assays
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Key papers and the live literature
Preprints →- POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma · New England Journal of Medicine 2022
Query for this target: (TITLE:"CD79b" OR ABSTRACT:"CD79b" OR TITLE:"CD79B" OR ABSTRACT:"CD79B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD79b, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd79b.json. Licence CC BY 4.0.